Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1

Open to people ages 18 years and up

• Histologically confirmed Merkel Cell Carcinoma (MCC)
• ECOG performance status ≤ 1
• MCC in an advanced, unresectable stage III or metastatic stage IV (includes patients who refused surgical resection or are not eligible for such surgical resection)
• Progressing on previous anti-PD-(L)1 antibody monotherapy within the last 12 weeks before planned first administration of study medication

• History of serious anti-PD-(L)1 therapy-related adverse reactions prohibiting further avelumab treatment
• More than one line of previous systemic anti-neoplastic therapy other than anti-PD-(L)1 antibody monotherapy
• Palliative radiation therapy of single lesions within 2 weeks before planned administration of study medication
• Presence of significant active or chronic disease (infections, immunodeficiencies, cardiovascular, psychiatric disorders)